Karyopharm Therapeutics Inc
25K0
Company Profile
Business description
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).
Contact
85 Wells Avenue
2nd Floor
NewtonMA02459
USAT: +1 617 658-0600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
228
Stocks News & Analysis
stocks
Ahead of earnings, is Nvidia a buy, a sell, or fairly valued?
Amid robust demand for semis, watch for any impact of in-house built chips and whether the supply chain is on track.
stocks
Higher interest rates boost earnings for ASX real estate platform
Interest rates are driving a spike in property listings.
stocks
After earnings, is Palantir a buy, a sell, or fairly valued?
With uncertainty regarding its total addressable market and competitive threats, here’s what we think of Palantir stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,880.70 | 7.70 | 0.09% |
| CAC 40 | 7,952.33 | 27.59 | -0.35% |
| DAX 40 | 24,139.53 | 184.60 | 0.77% |
| Dow JONES (US) | 49,760.56 | 56.09 | 0.11% |
| FTSE 100 | 10,276.05 | 10.73 | 0.10% |
| HKSE | 26,388.44 | 40.53 | 0.15% |
| NASDAQ | 26,088.20 | 185.92 | -0.71% |
| Nikkei 225 | 63,272.11 | 529.54 | 0.84% |
| NZX 50 Index | 13,063.06 | 17.27 | -0.13% |
| S&P 500 | 7,400.96 | 11.88 | -0.16% |
| S&P/ASX 200 | 8,630.40 | 0.60 | -0.01% |
| SSE Composite Index | 4,242.57 | 28.08 | 0.67% |